Immunotherapy Approved for Preventing Recurrence of Certain Skin Cancers
The FDA approved cemiplimab-rwlc as an adjuvant therapy for patients with cutaneous squamous cell carcinoma at high risk of...
Progress Against Cancer
The FDA approved cemiplimab-rwlc as an adjuvant therapy for patients with cutaneous squamous cell carcinoma at high risk of...
The FDA has approved the DNA-damaging agent in combination with immunotherapy for patients whose cancers have not progressed after...
The FDA has approved imlunestrant for certain patients with advanced ESR1-mutated breast cancer that has progressed following previous endocrine...
The FDA approved pembrolizumab and berahyaluronidase alfa-pmph as an injectable therapy for multiple tumor types. The U.S. Food and...
FDA expands selumetinib approval to include pediatric patients as young as 1 year with inoperable plexiform neurofibromas. The U.S....
The FDA has approved a delivery system that, once inserted into the bladder, delivers a local dose of the...
The FDA has approved zongertinib for patients with unresectable or metastatic non-squamous non-small cell lung cancer that has HER2...
The FDA has approved the first-in-class therapeutic dordaviprone for certain adult and pediatric patients with H3 K27M-mutated diffuse midline...
The FDA has approved sunvozertinib for certain patients with EGFR-mutated non-small Cell lung cancer. The U.S. Food and Drug...
The FDA has approved linvoseltamab-gcpt for certain patients with heavily pretreated multiple myeloma. The U.S. Food and Drug Administration...